Details of the Drug Combination

General Information of Drug Combination (ID: DC4XLJA)

Drug Combination Name
Eperisone Celecoxib
Indication
Disease Entry Status REF
Low Back Pain Phase 1 [1]
Component Drugs Eperisone   DM1SMAI Celecoxib   DM6LOQU
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Eperisone
Disease Entry ICD 11 Status REF
Muscle spasm MB47.3 Phase 3 [2]
Eperisone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated calcium channel (Cav) TTCRJKY NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Eperisone Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Celecoxib
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [3]
Lung cancer 2C25.0 Approved [3]
Osteoarthritis FA00-FA05 Approved [3]
Rheumatoid arthritis FA20 Approved [4]
Pain MG30-MG3Z Phase 3 [4]
Colon cancer 2B90.Z Investigative [3]
Familial adenomatous polyposis 2B90.Y Investigative [3]
Precancerous condition N.A. Investigative [3]
Celecoxib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Celecoxib Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03337607) Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain
2 ClinicalTrials.gov (NCT02040415) Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients. U.S. National Institutes of Health.
3 Celecoxib FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
5 Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305.
6 Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
7 Pfizer. Product Development Pipeline. March 31 2009.
8 Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
9 Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
10 Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
11 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
12 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.